Clinical significance of stanniocalcin-1 detected in peripheral blood and bone marrow of esophageal squamous cell carcinoma patients by Haizhu Song et al.
Song et al. Journal of Experimental & Clinical Cancer Research 2012, 31:
http://www.jeccr.com/31/1/RESEARCH Open AccessClinical significance of stanniocalcin-1 detected in
peripheral blood and bone marrow of esophageal
squamous cell carcinoma patients
Haizhu Song1, Biao Xu2 and Jun Yi2*Abstract
Background: Stanniocalcin-1 (STC-1) is a potential marker of disseminated tumor cells (DTCs). The aim of this study
was to examine STC-1 expression in peripheral blood (PB) and bone marrow (BM) of esophageal squamous cell
carcinoma (ESCC) patients, and to evaluate its clinical significance.
Methods: A total of 85 ESCC patients treated with radical resection were enrolled in this study.
Immunohistochemistry was used to detect STC-1 protein expression in ESCC tissues. Nested RT-PCR was used to
detect STC-1 mRNA expression in PB and BM.
Results: There were 71 cases (83.5%) showed a higher level of STC-1 protein expression in tumor tissues than in
adjacent normal tissues (P< 0.001). Furthermore, the frequencies of STC-1 mRNA expression detected in PB and BM
were 37.6% (32/85) and 21.2% (18/85), respectively, and together increased sensitivity to 48.2% (41/85), which was
much higher than that in patients with benign esophageal disease (5.0%, 2/40, P< 0.001). In addition, STC-1 mRNA
expression either in PB or BM was correlated with lymph metastasis, advanced stage and adverse 2-year progression
free survival (PFS). In a multivariate analysis using the Cox proportional hazard model, STC-1 expression in PB and/or
BM was an independent unfavorable prognostic factor for ESCC, apart from lymph metastasis and clinical stage.
Conclusions: STC-1 mRNA expression is a reliable marker for detection of DTCs in PB and BM of ESCC patients, and
STC-1-positive DTCs may be a promising tool for diagnosis and prognosis assessment in ESCC.
Keywords: Esophageal squamous cell carcinoma, Stanniocalcin-1, Disseminated tumor cells, Peripheral blood, Bone
marrow, Micrometastasis, PrognosisBackground
Esophageal squamous cell carcinoma (ESCC) comprises
the majority of esophageal cancer in China and it is char-
acterized by a high incidence and mortality rate [1]. Even
though this disease is surgically curable in the early
stages, patients often suffer asymptomatic metastasis that
is associated with a high mortality [2]. Evidences have
shown that, cancer cells from the original region may
disseminate into the peripheral blood (PB) or bone mar-
row (BM) in the early stage and survive without clinical
representation as micrometastasis, an important initial
step for recurrence and distant metastases [3,4]. Thus, it* Correspondence: njyijun@163.com
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reproduction in any medium, provided the oris clearly imperative to monitor these disseminated
tumor cells (DTCs), which may contribute to improved
diagnosis or prognosis and therefore more appropriate
treatments.
As a result of the removal by immune system, very few
DTCs exist and are undetected by normal methods. So
far many different techniques have been applied for
enriching and detecting DTCs, but the most commonly
used is conventional reverse-transcriptase polymerase
chain reaction (RT-PCR), because of the high degree of
sensitivity and specificity, allowing the detection of one
malignant cell among 106 ~ 107 monocytes [5]. Accord-
ingly, an appropriate marker used in RT-PCR would be
of a paramount importance, which should be expressed
only in tumor cells, but not in normal cells. Previousd This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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promising tumor marker, for its high expression level in
various of malignancies including ESCC, as compared
with adjacent normal tissues [6-8]. Therefore, we deter-
mined the STC-1 mRNA expression using nested RT-
PCR in PB and BM from ESCC patients treated with
radical resection, and their associations with clinico-
pathological features and 2 year progression-free survival
(PFS) were further eval
Methods
Study population
This study enrolled 85 ESCC patients treated with rad-
ical resection at Jinling Hospital from July 2006 to July
2008. Patients consisted of 54 males and 31 females, with
a median age of 62 (range, 44–83) years. Tumor stage
was conducted according to the 7th edition of the TNM
staging system of the International Union Against
Cancer [9], and patients were at stages I (n = 18), II
(n = 25), III (n = 33) and IV(n = 9, supraclavicular or para-
aortic lymph nodes metastasis). Cellular differentiation
was graded according to the WHO grading system.
Ethical approval was obtained from the hospital and
informed consent was obtained from all patients prior to
sample examination. Clinical follow-up data were avail-
able for all the patients. For each patient, 10 mL PB
before surgery was collected, and PB mononuclear cells
were isolated using Lymphocyte separation medium
(Sigma, St. Louis, USA) according to the manufacturer’s
protocol. Also, 5–10 mL of BM was aspirated from ribs
during surgical treatment, and mononuclear cells were
isolated from BM by Ficoll gradient centrifugation and
then aliquoted to isolate RNA. PB and BM samples from
40 patients with benign esophageal disease were also
collected.
Immunohistochemical staining
Formalin-fixed, paraffin-embedded samples used for
immunohistochemistry were sectioned at 2 μm thick-
ness. Sections were deparaffinized using xylene,
dehydrated by gradient ethanol, and then rehydrated with
deionized water. Heat-mediated antigen retrieval was run
by autoclave treatment (120°C for 2 min in 1 mmol/L
ethylenediaminetetraacetic acid [EDTA], pH of 8.0) and
then followed by cooling at room temperature. Incuba-
tion with a polyclonal goat anti-STC-1 antibody (diluted
1:200, Santa Cruz Biotechnology, CA, USA) was
performed overnight at 4°C. After washing with
phosphate-buffered saline (PBS), sections were then incu-
bated with donkey anti-goat secondary antibody (Santa
Cruz) for 30 min at room temperature. Coloration was
performed with 3,3-diaminobenzidine. Nuclei were coun-
terstained with hematoxylin. PBS was used as a negative
control for the staining reactions. Immunostaining resultswere evaluated independently by 3 pathologists. The
percentage of positive cells was rated as follows: 0 score
for 0–5%, 1 score for 6–25%, 2 scores for 26–50%, and 3
scores for more than 50%. The staining intensity was
rated as follows: 0 score for no staining, 1 score for weak
staining, 2 scores for moderate staining, and 3 scores for
strong staining [10]. The scores from the percentage and
intensity were added to an overall score, and the expres-
sion of STC-1 protein in ESCC with an overall score of 0
was designated as ‘negative’, 1–2 was designated as ‘low’,
3–4 was designated as ‘moderate’ and 5–6 was designated
as ‘high’.
Nested RT-PCR
Total RNA in mononuclear cells was extracted by Trizol
reagent (Invitrogen, Carlsbad, CA, USA) and RNA
concentration was measured by spectrophotometer (Bio-
Photometer, Eppendorf, Hamburg, German). Approxi-
mately 1 μg of total RNA was used for cDNA synthesis
using a PrimeScript™ 1st Strand cDNA Synthesis Kit
(TaKaRa, Shiga, Japan). PCR reaction was performed in a
25 μl volume comprised of 5 μl of DNA template,
10 ×Buffer, 0.15 mM dNTPs, 0.1 mM of each primer
and 0.5U of Ex Taq Hot Start Version (Takara). Primer
sequences and amplification conditions are listed in
Table 1 and have been described elsewhere [11]. PCR
products were identified on a 2% agarose gel containing
ethidium bromide. A resected ESCC tumor tissue and
water blank were used as positive and negative control,
respectively.
Statistical analysis
Statistical tests were carried out using SPSS version 16.0
(SPSS Inc., Chicago, IL, USA). The differential expres-
sions of STC-1 between tumor and adjacent normal spe-
cimens were calculated with Student’s t-test. Differences
in frequency were assessed by Chi-square test or Fisher’s
exact test. Overall survival curves were calculated using
the Kaplan-Meier method and compared by log-rank
testing. Multivariate Cox proportional hazard models
were used to define the potential prognostic significance
of individual parameter. P< 0.05 was taken as statisti-
cally significant.
Results
STC-1 protein expression profiles in ESCC tissue
We determined STC-1 protein expression in 85 pairs of
ESCC and matched normal tissues by immunohisto-
chemical staining. The representative immunohistochem-
ical results are shown in Figure 1(A-D). In total, there
were 71 cases (83.5%) showed a higher level of STC-1
protein expression in tumor tissues than in normal tis-
sues, and the average immunostaining scores in tumor
tissues were 3.08 ± 1.81 while in normal tissues was
Table 1 List of the nested PCR primers
Primers Sequences (5′-3′) Products PCR conditions
STC-1 (outer) CTTCACTCAAGCCAGGAGAGGGAAAGAGGAAA 890 bp 94°C for 30s, 62°C for 30s, 72°C for 1 min, 40 cycles
TGGTGTGTCAACACCCCTAAAATGATA
STC-1 (inner) GTGGCGGCTCAAAACTCAGCTGAA 645 bp 94°C for 30s, 60°C for 30s, 72°C for 1 min, 40 cycles
TTATGCACTCTCATGGGATGTGCGTT
β-actin CCCTGGACTTCGAGCAAGAGAT 531 bp 94°C for 30s, 55°C for 30s, 72°C for 1 min, 35 cycles
GTTTTCTGCGCAAGTTAGG
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of immunostaining scores per sample in tumor tissues
and adjacent normal tissues was shown in Figure 1F, the
rate of STC-1 protein high/moderate expression in ESCC
and normal tissues was 65.9% (56/85) and 7.1% (6/85),
respectively, which showed a significant difference
(P< 0.001).Figure 1 STC-1 protein expression in ESCC and matched normal tissu
(magnification× 200). (A) STC-1 negative in normal tissue; (B) low STC-1 e
tissue; (D) high STC-1 expression in tumor tissue. (E) The average immunos
Distribution of immunostaining scores per sample in tumor and adjacent nSTC-1 mRNA expression profiles in PB and BM from ESCC
patients
The frequencies of STC-1 mRNA expression detected in
PB and BM were 37.6% (32/85) and 21.2% (18/85),
respectively, and showed no correlations with each other
(P> 0.05), their combination increased the sensitivity to
48.2% (41/85) (Table 2). STC-1 mRNA detected in PBes determined by immunohistochemical staining
xpression in tumor tissue; (C) moderate STC-1 expression in tumor
taining scores of STC-1 expression in tumor and normal tissues; (F)
ormal tissues.
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moderate expression in parallel tumor tissues, regardless
of clinical staging (Table 3). Furthermore, in the 40 PB
and/or BM samples from patients with benign esopha-
geal disease, only 2 cases (5.0%) were found to be STC-1
mRNA-positive, this frequency was remarkably lower
than that in the cancer patients (P< 0.001). Figure 2
shows the typical PCR results.Figure 2 Profiles of STC-1 mRNA expression in the peripheral
blood (PB) and bone marrow (BM) of three ESCC patients. Neg,
a water blank was used as the negative control; Pos, a resected ESCC
tumor tissue was used as the positive control.Association between STC-1 mRNA expression and
clinicopathological features
As shown in Table 4, STC-1 mRNA expression in PB
and BM of ESCC patients were both associated with
lymph metastasis and clinical stage. However, there were
no correlations of STC-1 mRNA expression and patients’




peripheral blood bone marrow
STC-1 (+) (%) P-value STC-1 (+) (%) P-value
Gender 0.674 0.429
Male 54 19(35.2%) 10(18.5%)
Female 31 13(41.9%) 8 (25.8%)
Age 0.242 0.446
<60 35 11 (31.4%) 6(17.1%)
≥60 50 22 (44.0%) 12(24.0%)Association between STC-1 mRNA expression and ESCC
prognosis
To the follow-up deadline, there were 39 patients with
progression or relapse within 2 years after the end of sur-
gery. We performed univariate survival analyses to inves-
tigate the possible prognostic role of STC-1 expression
in ESCC. As shown in Figure 3, the STC-1 expression in
PB and BM were both associated with poor 2-year PFS
(mean 16.2 months (95%CI: 13.688-18.750) vs
20.2 months (95%CI: 18.677-21.738), P= 0.009, and mean
15.0 months (95%CI: 11.543-18.457) vs 19.7 months
(95%CI: 18.264-21.139), P= 0.003, respectively). Also in
combination, patients with STC-1 mRNA expression in
PB and/or BM showed a shortened PFS, as compared to
that with STC-1 negative expression (mean 16.7 monthsTable 2 STC-1 mRNA expression in peripheral blood and




STC-1 (+) STC-1 (−)
STC-1 (+) 9 23 0.223
STC-1 (−) 9 44
(+), positive; (−), negative.
Table 3 Correlation of STC-1 expression in ESCC tissue
and peripheral blood/bone marrow (n=85)
Protein expression
in ESCC tissue
peripheral blood /bone marrow
P-valueSTC-1 mRNA (+) STC-1 mRNA (−)
Stage I/II
STC-1 high/moderate 11 11 0.012
STC-1 low/negative 3 18
Stage III/IV
STC-1 high/moderate 24 7 0.008
STC-1 low/negative 3 8
(+), positive; (−), negative.(95%CI: 14.461-18.905) vs 20.6 months (95%CI: 19.014-
22.167), P= 0.005).
Furthermore, multiple Cox regression analysis was
used to verify whether the investigated variables includ-
ing STC-1 expression were valid predictors of outcome
after adjusting for potential confounding cofactors.Tumor site 0.632 0.547
Upper thoracic 17 5 (29.4%) 4 (23.5%)
Middle thoracic 33 12 (36.4%) 5 (15.2%)
Lower thoracic 35 15 (42.9%) 9 (25.7%)
Differentiation 0.615 0.575
Well 18 5 (27.8%) 3 (16.7%)
Moderate 38 15(39.5%) 7 (18.4%)
Poor 29 12(41.4%) 8 (27.6%)
T status 0.583 0.329
T1 ~ 2 51 18 (35.3%) 9(17.6%)
T3 ~ 4 34 14 (41.2%) 9(26.5%)
Lymph metastasis 0.000* 0.013*
N0 41 7(17.1%) 4(9.76%)
N1/N2/N3 44 25(56.8%) 14(31.8%)
Clinical stage 0.020* 0.029*
I/II 43 11(25.6%) 23 5(11.6%) 20
III/IV 42 21(50.0%) 33 13(31.0%) 9
*P< 0.05.
Figure 3 Correlation between STC-1 mRNA expression in (A) peripheral blood (PB), (B) bone marrow (BM), and (C) PB and/or BM with
2-year progression-free survival among 85 ESCC patients using Kaplan-Meier statistical analyses. (+), positive; (−), negative
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apart from lymph metastasis and advanced stage, were
independent factors for predicting an adverse 2-year PFS
for ESCC patients (Table 5).Discussion
Hematogenous metastasis is the main cause of the poor
outcomes for cancer patients, and there are many previ-
ous studies of DTCs that detach from the primary tumor,
enter the bloodstream and travel via circulation to
distant sites [12,13]. However, the relationships between
BM micrometastases (BMM) and clinical outcome of
ESCC are relatively insufficient [14]. BM is a major site
for tumor cell deposition and dissemination. Evidences
have shown that tumor cells spread into the BM while
the primary tumor is still in the early stages, and BM
acts as an intermediate site for target organ metastasis.
Studies of BM samples by various methods have indi-
cated that the presence or absence of BMM is associated
with the clinical outcome of patients with esophageal
carcinoma [15,16]. We currently investigated the DTCsTable 5 Multivariate analysis of clinicopathological
factors for 2 year progression-free survival (PFS) of 85
patients with ESCC
Characteristics Category RR (95%CI) P-value
Age ≥60 vs <60 years 1.500 (0.626-3.596) 0.363
Tumor differentiation Poor vs Well/Moderate 1.607 (0.658-3.925) 0.296
T status T3 ~ 4 vs T1 ~ 2 1.963 (0.814-4.733) 0.131
Lymph metastasis N1/N2/N3 vs N0 3.111 (1.276-7.583) 0.011*
Clinical stage III/IV vs I/II 3.046 (1.255-7.395) 0.013*
STC-1 expression
in PB and/or BM
Positive vs Negtive 3.348 (1.372-8.172) 0.007*
KPS scores ≥90 vs< 90 0.691 (0.281-1.703) 0.422
RR: Relative risk; PB: peripheral blood; BM: bone marrow; KPS: Karnofsky
performance status.
*P< 0.05.in PB and BM by nested RT-PCR, to further confirm
their clinical significance in ESCC.
Because PB and BM are mesenchymal tissues that do
not normally express epithelial cell markers, detection of
the expression of specific epithelial markers in the PB
and BM implies the presence of metastatic cancer cells.
Although many epithelial markers have been used previ-
ously, such as carcinoma embryonic antigen, cytokeratins
and survivin, it is important to identify new potential
biomarkers [14,15,17]. STC-1 is a kind of glycoprotein
hormone, first found in bony fish and later in humans
and mammals, with a highly conserved homology. Its
primary function in fish is prevention of hypercalcemia
and stimulation of phosphate reabsorption [18]. In mam-
mals, STC-1 appears to play multiple roles in a series of
biological processes, including pregnancy, lactation,
angiogenesis, cerebral ischemia, oxidative stress and
apoptosis [19-22]. Moreover, there is growing evidences
suggesting that STC-1 is involved in carcinogenesis [23].
STC-1 expression levels are universally much higher in
tumor tissues and cancer cell lines, such as hepatocellu-
lar, colorectal, ovarian, breast cancer and medullary
thyroid cancer, than those in corresponding normal
tissues [7,24-29]. Recently, Shirakawa et al [8] found that
STC-1 mRNA and protein are overexpressed in ESCC
tumors, compared with those in corresponding normal
tissues, which significantly correlates with an advanced T
status and poor prognosis for ESCC patients. This
observation suggests that STC-1 may be useful as a
tumor marker for ESCC. In fact, use of the STC-1
expression level as a diagnostic or prognostic biomarker
in the blood has been validated in breast, lung, colorectal
cancer, as well as hepatocellular carcinoma and leukemia
[11,25,30-33]. The detection of STC-1 mRNA in BM has
also been reported in breast cancer, which correlates
with multiple histopathological prognostic factors,
including primary tumor size, the number of positive
lymph nodes and TNM stage [33].
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the level of STC-1 protein expression in ESCC was much
higher than that in matched normal tissues, which
further confirmed STC-1 as a promising tumor marker
for ESCC. Moreover, STC-1 mRNA detection in PB and
BM showed good sensitivity and specificity, the frequen-
cies in PB and BM were 37.6% and 21.2%, respectively,
which was comparable with other epithelial markers
reported in ESCC. A previous study has indicated that
DTCs detected in PB of breast cancer could not be an
alternative to detect it in BM, because there are some
different characters with each other [34]. We also found
that DTCs detected in PB/BM had no correlations with
each other, and together increased the sensitivity to
48.2%, which was much higher than that in controls with
benign esophageal disease, and DTCs detected in PB and
BM of ESCC patients were both associated with lymph
metastasis, clinical stage and adverse prognosis.
These results indicated that, DTC detection in PB is a
non-invasive and more convenient method, but cannot
replace that in BM, their combination will contribute
to improve the test efficacy, and maybe useful as a
diagnostic or prognositc biomarker.
Currently, the most important conventional prognostic
factors for ESCC are the lesion length, invasion depth
and lymph metastasis at the time of diagnosis (pTNM),
which largely determines the treatment plan. However,
the actual outcome of the disease is not entirely consist-
ent with these clinicopathological parameters. Some
patients at an early stage suffer tumor recurrence or
metastasis soon after initial treatment, and others at
advanced stages have long-term survival [35,36], which
maybe due to the different molecular biology character-
istics of their tumors, and DTC status may play an
important role. A frequently updated pTNM still fails to
discriminate between degrees of malignancy. Thus, in
addition to these clinicopathological parameters, molecu-
lar markers are being sought in ESCC, and DTC dection
has shown a promising prospect. Our study confirmed
that DTC detected either in PB or BM of ESCC patients,
which was represented by STC-1 mRNA expression,
were both associated with an adverse 2 year PFS. These
results were further verified with a Cox proportional
hazard model, in which STC-1 mRNA expression in PB
and/or BM from ESCC patients was found to be an
independent unfavorable prognostic factor, apart from
regional lymph metastasis and advanced stage. This
suggests that DTC status may be a key factor determing
the ESCC outcome. Thus, if a patient is found to be
DTC-positive, comprehensive treatment including
adjuvant radiochemotherapy should be recommended,
which may improve patient survival by eliminating the
DTCs and suppressing the micrometastasis.Conclusions
In this study, we performed nested RT-PCR to detect a
potential representative biomarker of DTCs, STC-1
mRNA expression in PB and BM from ESCC patients.
We found that STC-1 mRNA expression is a reliable
marker to detect DTCs, and DTC positivity may be
a promising indicator for diagnostic and prognostic
assessment of ESCC.
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